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Current recommendations endorsed by the American Heart 
Association and the American College of Cardiology for 
secondary prevention of coronary disease include dietary lim- 
itation of total fat to -<30%, saturated fat to <7%, and 
cholesterol to <200 mg/day (1). Although the results of 
randomized studies of diet have been inconsistent, these 
guidelines are based on the known relations between dietary 
fat intake, serum lipids and coronary events. The objective with 
such a diet is to have favorable ffects of decreasing total and 
low density lipoprotein cholesterol and of increasing high 
density lipoprotein cholesterol. The evidence has become 
more compelling that comprehensive risk factor modification, 
including a low fat, low cholesterol, high carbohydrate diet, has 
a favorable impact on serum lipids and that it reduces angio- 
graphic progression of coronary disease and hospital admis- 
sions for coronary events (2). 
Aside from the well accepted goal of serum lipid modifica- 
tion, a number of dietary interventions have been proposed to 
be cardioprotective by other mechanisms. In recent trials of 
nutritional supplements, ome reports, such as that of the 
antioxidant beta-carotene, have been disappointing (3), and 
others have been promising, such as the Cambridge Heart 
Antioxidant Study (CHAOS) evaluating vitamin E use (4). On 
the basis of epidemiologic data, many physicians recommend 
modest alcohol intake as an effective measure for prevention of 
coronary disease vents (5). 
Two general types of diet have drawn considerable atten- 
tion recently: the "Mediterranean" diet, high in monounsatu- 
rated fat in olive oil, fruits, vegetables and wine; and diets high 
in omega-3 fatty acids, either in the form of oily fish (6) or the 
omega-3 fatty acid precursor alpha-linolenic acid, found in 
soya oil and canola (rapeseed) oil. The current study by de 
Lorgeril et al. (7), in this issue of the Journal, evaluated a
combination of these two diets, with the intervention i volving 
instructions to eat more vegetables and fruit to supply antioxi- 
dants and to substitute canola oil margarine for butter and 
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cream to supply alpha-linolenic acid. Plasma samples from a 
subgroup of patients howed that the investigators were suc- 
cessful with the intervention at increasing antioxidants (vita- 
mins E and C) and omega-3 fatty acid levels, although lipopro- 
tein profiles were not affected. Proposed mechanisms of 
benefit of supplemental omega-3 fatty acids supported by 
experimental data include antithrombotic effects through changes 
in eicosanoids and platelet function, anti-inflammatory effects 
through changes in white blood cell function and antiarrhythmic 
effects through effects on membranes. 
De Lorgeril et al. (7) found that dietary intervention 
reduced the 2-year rates of secondary events of unstable 
angina, stroke, heart failure and venous and arterial emboli- 
zation, and when combined with the primary events, this 
represented a risk ratio (RR) of 0.24 (95% confidence interval 
[CI] 0.13 to 0.44, p < 0.0001). These results include twice the 
total number of events as were in the primary report (8), and 
de Lorgeril thereby extend the original findings of a reduction 
in major events (cardiac-related death and nonfatal myocardial 
infarction) (RR 0.27, 95% CI 0.12 to 0.59). The current report 
(7) demonstrates a consistency in the relative reduction of the 
primary and secondary events. There was a less striking 
reduction in minor events of stable angina, restenosis after 
angioplasty, thrombophlebitis and myocardial revasculariza- 
tion. 
These remarkable results are almost certainly largely due to 
factors other than a true treatment effect. The 76% reduction 
in major clinical events reported in this study (7) is well beyond 
the range that would be expected, especially from a simple 
dietary intervention consisting of a single patient visit followed 
by an 8-week visit and then yearly visits. Several factors may 
have led to an overestimation f the true treatment effect. The 
effect was most likely overestimated in part because of chance. 
The analyses in the current report were not the primary end 
point of the trial, and no correction was made for multiple 
analyses or for the post hoc nature of the analysis. Although 
the analysis was reported as "intention to treat," the dropout 
and lost to follow-up rates were high at between 7% and 8% 
and included patients who were removed from the study 
because of intolerance of the diet. The study was conducted at 
a single center, with the attendant limitations of small sample 
size (605 patients) for a secondary prevention trial and lack of 
generalizability. Even with a blinded end point review commit- 
tee, a single-center study, especially when not double blinded, 
provides greater potential for bias because of the lesser 
separation of clinical data recording, collection, management, 
analysis and interpretation. 
Despite the probable overestimation of treatment effect, the 
results of this report, along with the original Lyon Diet Heart 
Study report (8), the Diet and Reinfarction Trial (6) study of fish 
oil, and the CHAOS study of vitamin E (4) provide support for 
the concept hat different diets may have complex effects on 
modifying coronary risk. The currently accepted recommenda- 
tions to limit total and saturated fat may be only part of the story, 
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and rather than chewing the fat, we should be studying in large, 
multicenter andomized trials the effect of swallowing it. 
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